Gravity Analytica

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

CALC 11.21.2024

SERA-AI Powered Highlights

Drug:AuxoraTM-001 AuxoraTM

Diseases:acute pancreatitis

Diseases:COVID pneumonia

Diseases:acute kidney disease

Diseases:asparaginase-induced pancreatic toxicity

Date of Upcoming Event:2024-12-04

Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference

Full Press Release SEC Filings Our CALC Tweets

About Gravity Analytica

Recent Filings

LA JOLLA, Calif.,Nov. 21, 2024/PRNewswire/ --CalciMedica Inc.("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced thatRachel Leheny, Ph.D., Chief Executive Officer, will present at the Piper Sandler 36^thAnnual Healthcare Conference onWednesday, December 4, 2024, at9:10 a.m. ET/6:10 a.m. PT.

A live webcast of the presentation can be accessed in the "Upcoming Events" section ofCalciMedica'sIR website athttps://ir.calcimedica.com/. A replay of the webcast will be archived on the Company's website for 90 days.

AboutCalciMedicaCalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate AuxoraTM has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO –NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA –NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) and continuing to support the ongoing Phase 1/2 trial (called CRSPA –NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT). CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visitwww.calcimedica.com.

CalciMedica Contact:

Investors and MediaArgot PartnersSarah Sutton/Kevin Murphycalcimedica@argotpartners.com(212) 600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-302312144.html

SOURCECalciMedica, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com